Effects of Centrally Acting Angiotensin Converting Enzyme Inhibitors on Functional Decline in Patients with Alzheimer's Disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2014-04-23

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/JAD-131694PMID 24496072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Geriatric Depression Scale

  2017influential reference
• The Quick Mild Cognitive Impairment screen correlated with the Standardized Alzheimer's Disease Assessment Scale-cognitive section in clinical trials.

  2014cited by this paper
• Which part of the Quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia?

  2013cited by this paper
• Angiotensin System–Blocking Medications Are Associated with Fewer Falls over 12 Months in Community‐Dwelling Older People

  2013cited by this paper
• Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia

  2013cited by this paper
• Associations of Angiotensin Targeting Antihypertensive Drugs with Mortality and Hospitalization in Primary Care Patients with Dementia

  2013cited by this paper
• For peer review only Effects of Centrally Acting Angiotensin Converting Enzyme Inhibitors on the Rate of Cognitive Decline in Dementia

  2013cited by this paper
• Cornell Scale for Depression in Dementia.

  2013influential reference
• A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial

  2013influential reference
• Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging

  2013influential reference
• Assessment scales in dementia

  2012cited by this paper
• Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism.

  2012cited by this paper
• Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.

  2012cited by this paper
• Blood Pressure Trajectories From Midlife to Late Life in Relation to Dementia in Women Followed for 37 Years

  2012cited by this paper
• Comparison of the quick mild cognitive impairment (Qmci) screen and the SMMSE in screening for mild cognitive impairment

  2012influential reference
• Calcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome

  2012cited by this paper
• Central angiotensin II‐induced Alzheimer‐like tau phosphorylation in normal rat brains

  2012cited by this paper
• The Renin-Angiotensin System and Antihypertensive Drugs in Alzheimer's Disease: Current Standing of the Angiotensin Hypothesis?

  2012cited by this paper
• The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial

  2012cited by this paper
• Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.

  2012cited by this paper
• Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats.

  2011cited by this paper
• Apolipoprotein E genotype‐specific short‐term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients—an open‐label trial

  2011cited by this paper
• A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients

  2011cited by this paper
• Perindopril, a centrally active angiotensin‐converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease

  2011cited by this paper
• Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia.

  2011cited by this paper
• Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias

  2011cited by this paper
• Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats

  2011cited by this paper
• ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

  2010cited by this paper
• Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.

  2010cited by this paper
• Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

  2010cited by this paper
• ACE variants and association with brain Aβ levels in Alzheimer's disease.

  2010cited by this paper
• Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.

  2009influential reference
• The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition

  2009cited by this paper
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

  2009cited by this paper
• Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

  2009cited by this paper
• Angiotensins in Alzheimer's disease - friend or foe?

  2009cited by this paper
• Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

  2009cited by this paper
• Effects of Antihypertensive Drug Treatment on the Risk of Dementia and Cognitive Impairment

  2008cited by this paper
• Angiotensin‐converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE‐1 to cerebral amyloid angiopathy

  2008cited by this paper
• Effects of cardiovascular medications on rate of functional decline in Alzheimer disease.

  2008cited by this paper
• Screening performance of the 15-item geriatric depression scale in a diverse elderly home care population.

  2008cited by this paper
• Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial

  2007cited by this paper
• Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly.

  2007cited by this paper
• Relationship of vascular risk to the progression of Alzheimer disease

  2006cited by this paper
• Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

  2006cited by this paper
• Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment

  2006influential reference
• The N‐terminal active centre of human angiotensin‐converting enzyme degrades Alzheimer amyloid β‐peptide

  2005cited by this paper
• Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.

  2005cited by this paper
• Predictors of adherence with antihypertensive and lipid-lowering therapy.

  2005cited by this paper
• Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor*

  2005cited by this paper
• Midlife cardiovascular risk factors and risk of dementia in late life

  2005cited by this paper
• Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline.

  2005cited by this paper
• Angiotensin‐Converting Enzyme Inhibitors and Incidence of Alzheimer's Disease in Japan

  2004cited by this paper
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int

  2004cited by this paper
• Reliability of Monitoring the Clinical Dementia Rating in Multicenter Clinical Trials

  2004cited by this paper
• Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression

  2004cited by this paper
• Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

  2004cited by this paper
• Angiotensin as a target for the treatment of Alzheimer’s disease, anxiety and depression

  2004cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

  2003cited by this paper
• Influence of losartan and atenolol on memory function in very elderly hypertensive patients

  2003cited by this paper
• Captopril and Enalapril Improve Cognition and Depressed Mood in Hypertensive Patients

  2003cited by this paper
• Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

  2003cited by this paper
• The Effect of Quinapril on Functional Status of Elderly Patients with Diastolic Heart Failure

  2003cited by this paper
• Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial

  2002cited by this paper
• Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study.

  2002cited by this paper
• Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity*

  2001cited by this paper
• Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.

  2001cited by this paper
• Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.

  1999cited by this paper
• Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease

  1999cited by this paper
• Perindopril for elderly people with chronic heart failure: the PEP‐CHF study

  1999cited by this paper
• Alzheimer's Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial

  1997cited by this paper
• Cornell Scale for Depression in Dementia

  1997cited by this paper
• A Guide to the Standardized Mini-Mental State Examination

  1997cited by this paper
• Improved Reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) Compared with the Alzheimer's Disease Assessment Scale (ADAS)

  1996cited by this paper
• Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.

  1992cited by this paper
• Validity and reliability of the Dysfunctional Behaviour Rating Instrument

  1991cited by this paper
• The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

  1991cited by this paper
• Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination.

  1991influential reference
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper
• Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.

  1990cited by this paper
• Geriatric Depression Scale.

  1988cited by this paper
• Cornell Scale for Depression in Dementia.

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Assessment of older people: self-maintaining and instrumental activities of daily living.

  1969influential reference

• Clinical outcomes of antihypertensive medication use in people with dementia: a systematic review and meta-analysis.

  2025cites this paper
• Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure

  2025cites this paper
• Lupus autoantibodies initiate neuroinflammation sustained by continuous HMGB1:RAGE signaling and reversed by increased LAIR-1 expression

  2024cites this paper
• Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

  2023cites this paper
• Design of new captopril mimics as promising ACE inhibitors: ADME, pharmacophore, molecular docking and dynamics simulation with MM-PBSA and PCA calculations

  2023cites this paper
• Acute Myocardial Infarction and Risk of Cognitive Impairment and Dementia: A Review

  2023cites this paper
• Utilizing Proteomic Approaches to Uncover the Neuroprotective Effects of ACE Inhibitors: Implications for Alzheimer’s Disease Treatment

  2023cites this paper
• Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease.

  2023cites this paper
• Diverse biological functions of the renin‐angiotensin system

  2023cites this paper
• Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer’s disease: A nationwide population-based cohort study

  2023influential citation
• Genetic Evidence for Protective Effects of Angiotensin-Converting Enzyme Against Alzheimer Disease But Not Other Neurodegenerative Diseases in European Populations

  2022cites this paper
• Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers

  2022cites this paper
• The Correlation between Two Angiotensin-Converting Enzyme Inhibitor’s Concentrations and Cognition

  2022cites this paper
• Cognitive dysfunction in SLE: An understudied clinical manifestation.

  2022cites this paper
• Leucine and perindopril to improve physical performance in people over 70 years with sarcopenia: the LACE factorial RCT

  2022cites this paper
• Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice

  2022cites this paper
• Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.

  2022cites this paper
• ACE and ACE2: insights from Drosophila and implications for COVID-19

  2021cites this paper
• Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches

  2021cites this paper
• Angiotensin (1–7) Expressing Probiotic as a Potential Treatment for Dementia

  2021cites this paper
• Breast Milk: A Source of Functional Compounds with Potential Application in Nutrition and Therapy

  2021cites this paper
• The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status

  2021cites this paper
• Involvement of the Renin-Angiotensin System in Stress: State of the Art and Research Perspectives

  2021cites this paper
• Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease

  2020cites this paper
• Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial

  2020cites this paper
• CIA_A_253116 743..754

  2020influential citation
• Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system.

  2020cites this paper
• Blood–brain barrier dysfunction: the undervalued frontier of hypertension

  2020cites this paper
• The Brain AT2R—a Potential Target for Therapy in Alzheimer’s Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics

  2020cites this paper
• Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Rescue Memory Defects in Drosophila-Expressing Alzheimer’s Disease-Related Transgenes Independently of the Canonical Renin Angiotensin System

  2020influential citation
• Using the Mouse to Model Human Diseases: Cognitive Impairment in Systemic Lupus Erythematosus

  2020cites this paper
• The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI).

  2020cites this paper
• Safety evaluation of high‐dose intake of casein‐derived peptide Met‐Lys‐Pro in healthy adults: A randomized, double‐blind, placebo‐controlled trial

  2020cites this paper
• Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?

  2019cites this paper
• Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer’s Disease

  2019cites this paper
• Renin-angiotensin system and Alzheimer's disease pathophysiology: From the potential interactions to therapeutic perspectives.

  2019cites this paper
• Neuropsychiatric Disorders in Chronic Kidney Disease

  2019cites this paper
• Brain Vasculature and Cognition.

  2019cites this paper
• Kehoe, P. G. (2018). The coming of age of the angiotensin hypothesis in Alzheimer's disease: Progress toward disease prevention and treatment?

  2018cites this paper
• N-domain of angiotensin-converting enzyme hydrolyzes human and rat amyloid-β(1-16) peptides as arginine specific endopeptidase potentially enhancing risk of Alzheimer’s disease

  2018cites this paper
• The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s Disease: Progress Toward Disease Prevention and Treatment?

  2018cites this paper
• Targeting Renin–Angiotensin System Against Alzheimer’s Disease

  2018cites this paper
• Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors

  2018cites this paper
• Connecting the brain cholesterol and renin–angiotensin systems: potential role of statins and RAS‐modifying medications in dementia

  2018cites this paper
• Obesity as a risk factor for Alzheimer's disease: the role of adiponectin

  2018cites this paper
• Вплив еналаприлу на функціональний стан центральної нервової системи при експериментальній хворобі Альцгеймера

  2018cites this paper
• Influence of enalapril on the functional state of the central nervous system in experimental Alzheimer’s disease

  2018cites this paper
• Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease

  2017cites this paper
• Can Angiotensin-Converting Enzyme Inhibitors Slow the Progression of Cognitive Decline In Elderly Patients With Dementia?

  2017cites this paper
• Cognitive Screening Instruments

  2017cites this paper
• Kidney-brain axis inflammatory cross-talk: from bench to bedside.

  2017cites this paper
• Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer's Disease using a Drosophila Model

  2017cites this paper
• Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

  2017cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Target Identification and Characterization in Transgenic Cardiovascular Disease Models of Atherosclerosis and Heart Failure

  2017cites this paper
• The Quick Mild Cognitive Impairment Screen (Q mci )

  2017cites this paper
• Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence.

  2016cites this paper
• P3‐096: Secondary Analyses of International Genomics of Alzheimer's Project Stage I GWAS Summary Data Identifies Additional Variants Associated With Late‐Onset Alzheimer's Disease

  2016cites this paper
• Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis.

  2016cites this paper
• Renin-Angiotensin-System Modulation may slow the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease

  2016cites this paper
• Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia

  2016cites this paper
• Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro.

  2016cites this paper
• Biochemical and Radiological Markers of Alzheimer’s Disease Progression

  2016cites this paper
• Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies

  2016cites this paper
• Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population

  2016cites this paper
• Angiotensin converting enzyme serum activities: Relationship with Alzheimer's disease.

  2016cites this paper
• A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

  2016cites this paper
• Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer’s Disease

  2016cites this paper
• Perindopril Attenuates Lipopolysaccharide-Induced Amyloidogenesis and Memory Impairment by Suppression of Oxidative Stress and RAGE Activation.

  2016cites this paper
• The Quick Mild Cognitive Impairment (Qmci) screen: developing a new screening test for mild cognitive impairment and dementia

  2015cites this paper
• Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia

  2015cites this paper
• Modulation of Renin‐Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease

  2015cites this paper
• Mood-Related Effects of Medications Prescribed for Non-Psychiatric Indications

  2015cites this paper
• The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.

  2015cites this paper
• Medical genetics-based drug repurposing for Alzheimer's disease.

  2015cites this paper
• Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress

  2015cites this paper
• The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease

  2015cites this paper
• The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.

  2015cites this paper
• Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes

  2014cites this paper
• Renin Angiotensin Aldosterone System Inhibition in Controlling Dementia-Related Cognitive Decline

  2014cites this paper
• The role of epigenetics in the treatment of Alzheimer's disease

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies

  2014cites this paper
• Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry

  2014cites this paper